Introduction The purpose of the quality standards document is to provide healthcare professionals, commissioners, service providers and patients with a guide to standards of care that should be met for the investigation and management of pulmonary nodules in the UK, together with measurable markers of good practice. Methods Development of British Thoracic Society (BTS) Quality Standards follows the BTS process of quality standard production based on the National Institute for Health and Care Excellence process manual for the development of quality standards. results 7 quality statements have been developed, each describing a key marker of high-quality, costeffective care for the investigation and management of pulmonary nodules, and each statement is supported by quality measures that aim to improve the structure, process and outcomes of healthcare. Discussion BTS Quality Standards for the investigation and management of pulmonary nodules form a key part of the range of supporting materials that the Society produces to assist in the dissemination and implementation of guideline recommendations.
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IntroDuctIon
The British Thoracic Society (BTS) has been at the forefront of the production of guidelines for best clinical practice in respiratory medicine since the Society was established over 30 years ago. The Society's guideline production process is accredited by National Institute for Health and Care Excellence (NICE) Accreditation (November 2011, renewed in 2017), and the Society's Guideline Production Manual 1 setting out the detailed methodology and policy for the production of guidelines is reviewed annually by the BTS Standards of Care Committee (SOCC).
A statement on quality standards based on each BTS guideline is a key part of the range of supporting materials that the Society produces to assist in the dissemination and implementation of a guideline's recommendations.
The purpose of the quality standards document is to provide commissioners, healthcare professionals, planners and patients with a guide to standards of care that should be met for pulmonary nodule investigation and management in the UK, together with measurable markers of good practice.
BTS quality standards are intended for: ► healthcare professionals to allow decisions to be made about care based on the latest evidence and best practice ► people with pulmonary nodules undergoing investigation and treatment to enable understanding of what services they should expect from their healthcare provider ► service providers to be able to quickly and easily examine the clinical performance of their organisation and assess the standards of care they provide ► commissioners so that they can be confident that the services they are purchasing are high quality and cost-effective. NICE Quality Standards and the NICE Quality Standards Process Guide 2 were used as a model for the development of BTS Quality Standards.
A quality standard is a set of specific, concise statements that: ► act as markers of high-quality, cost-effective patient care across a pathway or clinical area, covering treatment or prevention ► are derived from the best available evidence. The rationale for these quality standards is drawn from evidence and recommendations summarised in the BTS Guidelines for the Investigation and Management of Pulmonary Nodules. 3 Each quality standard includes the following:
Open Access ► A quality statement, which describes a key marker of high-quality, cost-effective care for this condition. ► Quality measures, which aim to improve the structure, process and outcomes of healthcare. The quality measures are not intended to be new sets of targets or mandatory indicators for performance management that need to be collected. The quality measures are specified in the form of a numerator and a denominator, which define a proportion or ratio (numerator/denominator). It is assumed that the numerator is a subset of the denominator population. The suggested numerator and denominator are provided to allow healthcare professionals and service providers to examine their clinical performance in relation to each quality standard. It is recognised that no national quality indicators will be available for this condition, and institutions will need to agree locally what information is required for the denominator to be used in each case, and what the expected level of achievement should be, given local circumstances. A brief description about the quality standard in relation to each audience is given.
The main source references for these quality standards are: ► BTS Guidelines for the Investigation and Management of Pulmonary Nodules, 2015. There is no specific order of priority associated with the list of quality standards. The document was made available on the BTS website for public consultation for the period from 13 March to 10 April 2017.
MethoD of workIng
Following further revision, the document was submitted for approval to the BTS Standards of Care Committee in October 2017.
The Quality Standards document will be reviewed in 5 years from the date of publication or following the publication of a revised Guideline whichever is sooner. 
Relevant existing indicators

Local multidisciplinary team (MDT) minutes/database/audit
National data sources National Lung Cancer Audit, Society for Cardiothoracic Surgery Thoracic Registry People with solid pulmonary nodules have their nodules assessed by semi-automated volumetry in preference to manual diameter measurements where possible and appropriate (eg, for smaller nodules and for measuring doubling time, when growth not obvious).
Rationale
To ensure patients with solid pulmonary nodules on CT have their nodule(s) assessed by the most accurate method, where possible to guide appropriate use of interval imaging and recommendation for further workup. Note: To ensure accuracy of comparative measurements, serial volumetry should be measured using the same CT settings, same software and release version.
Other information
► BTS Pulmonary Nodule Risk Prediction Calculator https://www. brit-thoracic. org. uk/ standards-ofcare/ guidelines/ bts-guidelines-for-the-investigation-and-management-of-pulmonary-nodules/ btspulmonary-nodule-risk-prediction-calculator/ (to be read in conjunction with the relevant sections of the above guideline). Rationale PET-CT examinations undertaken for assessment of solid pulmonary nodules are reported using qualitative assessment with an ordinal scale to define FDG uptake as absent, faint, moderate or intense, in relation to background lung tissue and mediastinal blood pool, to facilitate use of the Herder risk prediction model. The Herder risk prediction model is the most accurate at predicting malignancy in solid pulmonary nodules and has been validated in a UK population. It uses clinical and radiological factors in conjunction with FDG uptake within the pulmonary nodule to determine the risk of malignancy. The incorporation of FDG uptake has a synergistic effect on the predictive accuracy of clinicoradiological prediction models but is dependent on the accurate classification of FDG uptake within solid pulmonary nodules using qualitative assessment with an ordinal scale. The standardisation of reporting of FDG uptake within solid pulmonary nodules on PET-CT facilitates reliable reproducibility of the Herder risk prediction model in clinical practice.
Open Access Quality measure Structure: ► Evidence that PET-CT reports for characterisation of solid pulmonary nodules are reported using qualitative assessment with an ordinal scale to define FDG uptake with nodules. Process: ► Proportion of patients undergoing PET-CT for characterisation of solid pulmonary nodules with FDG uptake within nodules categorised using qualitative assessment with an ordinal scale. ► Numerator: number of patients undergoing PET-CTs performed for characterisation of solid pulmonary nodules with FDG uptake within the nodules categorised using qualitative assessment with an ordinal scale. ► Denominator: number of patients undergoing PET-CTs performed for characterisation of solid pulmonary nodules.
Description of what the quality statement means for each audience
Service providers: ► Ensure that patients have timely access to PET-CT for characterisation of solid pulmonary nodules.
Healthcare professionals who report PET-CT ► Ensure standardisation of reporting of FDG uptake within solid pulmonary nodules on PET-CT using qualitative assessment with an ordinal scale. Commissioners: ► Commission PET-CT for the characterisation of solid pulmonary nodules. People having PET-CT undertaken for assessment of solid pulmonary nodules ► Have their scans reported to facilitate the use of the Herder risk prediction model, one of the most accurate models in predicting malignancy in solid pulmonary nodules.
Relevant existing indicators
Local MDT minutes/database/audit National data sources National Lung Cancer Audit, Society for Cardiothoracic Surgery Thoracic Registry Faint: uptake less than or equal to mediastinal blood pool. Moderate: uptake greater than mediastinal blood pool. Intense: uptake markedly greater than mediastinal blood pool.
Quality statement 4 Rationale
People with pulmonary nodules confirmed on CT are offered discharge, further surveillance, further workup or treatment according to BTS Guidelines (see Box 1 for specific recommendations) To ensure that patients are not followed up inappropriately where the risk of follow-up is likely to outweigh the benefit. To ensure that patients with larger nodules are managed according to assessment of risk of malignancy by further surveillance, further workup or treatment. Quality measure Structure: ► Evidence that local arrangements are in place to apply BTS guidelines to patients with pulmonary nodules to ensure they are offered discharge, further surveillance, further workup or treatment appropriately.
Open Access To maximise the surgical resection rate for early stage lung cancer and to allow geographical and temporal comparison of resection rates to instruct service development.
To ensure an appropriate surgical strategy for resection that minimises lobectomy for benign disease, ensures anatomical resection for all pulmonary nodules confirmed as lung cancer and that, where appropriate, a completion lobectomy occurs during the same anaesthetic.
Quality measure Structure:
► Evidence of local arrangements and written clinical protocols that ensure people with pulmonary nodules considered for definitive treatment and suitable for surgical intervention are offered lobectomy with pathological confirmation of malignancy by frozen section, if not previously confirmed, or anatomical segmentectomy if unfit for lobectomy. Process: ► Overall proportion of patients who have pulmonary nodules with pathological confirmation of malignancy that undergo surgical resection. ► Proportion of patients undergoing lobar or segmental resection of malignant pulmonary nodules as one definitive procedure. ► Proportion of patients undergoing wedge or segmental resection of pulmonary nodules with eventual benign diagnosis.
Numerator 1: ► Number of patients who have pulmonary nodules with pathological confirmation of malignancy that undergo surgical resection.
Open Access
Denominator 1: ► Total number of patients who have pulmonary nodules with pathological confirmation of malignancy. Numerator 2: ► Number of patients undergoing lobectomy with intraoperative frozen section analysis, or undergoing anatomic segmentectomy where not fit for lobectomy. Denominator 2: ► Number of patients undergoing resection of pulmonary nodules without a preoperative diagnosis who are subsequently confirmed malignant. Numerator 3: ► Number of patients undergoing resection of pulmonary nodules with an eventual benign diagnosis who undergo lobectomy. Healthcare professionals ► Ensure surgical involvement in MDT discussion of pulmonary nodules, and ensure that surgical strategy is appropriate for the clinical situation. Commissioners: ► Commission specialist thoracic surgical services that offer lobectomy with pathological confirmation of malignancy by frozen section, if not previously confirmed, or anatomical segmentectomy, if unfit for lobectomy. Services will be supported by an expert lung cancer MDT. People with pulmonary nodules considered for definitive treatment and suitable for surgical intervention ► Should be treated at specialist centres with adequate provision for preoperative assessment, and intraoperative management for both diagnosis and resection.
Relevant existing indicators
Local MDT minutes/database/audit National data sources National Lung Cancer Audit, Society for Cardiothoracic Surgery Thoracic Registry People with pulmonary nodules considered for definitive treatment but who decline or who are unsuitable for surgery are offered ablative* non-surgical treatment where safe.
Rationale
People who are unfit or decline surgery still stand to gain a lot from having early-stage lung cancer treated with curative intent. Such patients should therefore be offered alternative treatment with curative intent. The outcome of treatment is similar whether in biopsy confirmed malignancy or where unconfirmed.
Structure:
► Evidence of local arrangements and written clinical protocols to ensure that people with pulmonary nodules considered for definitive treatment but who decline or who are unsuitable for surgery are offered ablative non-surgical treatment where safe.
Open Access Healthcare professionals: ► Offer referral to people with pulmonary nodules who decline or who are unsuitable for surgery for ablative non-surgical treatment where safe. Commissioners: ► Ensure they commission services for people with pulmonary nodules who decline or who are unsuitable for surgery so that they can be offered ablative non-surgical treatment where safe. People with pulmonary nodules who decline or who are considered unsuitable for surgery ► Are offered ablative non-surgical treatment where safe.
Relevant existing indicators
Local MDT minutes/database/audit National data sources National Lung Cancer Audit, Society for Cardiothoracic Surgery Thoracic Registry People with pulmonary nodules confirmed on CT are offered verbal and written information that allows them to make an informed choice about their management. Rationale
People with pulmonary nodules confirmed on CT should be provided with verbal and written information that allows them to make an informed choice about their management.
Quality measure
Structure: ► Evidence of local arrangements and written clinical protocols to ensure that people with pulmonary nodules confirmed on CT are offered verbal and written information that allows them to make an informed choice about their management.
Process:
► Proportion of people with pulmonary nodules confirmed on CT who are offered verbal and written information that allows them to make an informed choice about their management. Numerator: ► The number of people with pulmonary nodules confirmed on CT who are offered verbal and written information that allows them to make an informed choice about their management. Denominator: ► The number of people with pulmonary nodules confirmed on CT excluding nodules with obvious benign features.
Open Access
Description of what the quality statement means for each audience Service providers: ► Ensure there are systems in place to ensure people with pulmonary nodules confirmed on CT are offered verbal and written information that allows them to make an informed choice about their management. Healthcare professionals: ► Offer people with pulmonary nodules confirmed on CT verbal and written information that allows them to make an informed choice about their management. Commissioners: ► Ensure they commission services where people with pulmonary nodules confirmed on CT are offered verbal and written information that allows them to make an informed choice about their management.
People with pulmonary nodules confirmed on CT ► Are offered verbal and written information that allows them to make an informed choice about their management. This provides patients (and their carers) with the opportunity to ask questions and make comments in connection with the proposed management and about their care in general. They should be able to appreciate the balance of benefits and risks concerning nodule management.
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